**UKINETS bitesize guidance**

**Goblet Cell Carcinoma**

**PAGE 1 - MANAGEMENT ALGORITHM**

- **Appendectomy**
- **Suspected ovarian/peritoneal malignancy** - biopsy / surgical debulking

**GCC identified**

Refer patient to appropriate specialist MDT/ Centre

**Imaging**

CT

SRS/Ga68 PET - rarely positive [1]. 7FDG-PET in Tang C

**Stage - AJCC/UICC TNM7**

Classify - Tang criteria [2]

Serum Markers - not CgA but CA125, CEA, CA19.9 may be useful (unproven)

**Consider completion right hemi-colectomy**

Areas of debate:

- Tang A / localised (T1/2N0)
- GCC [2,3]
- Oophorectomy [3]

**Consider referral to specialist centre for consideration of Cytoreductive Surgery +/- HIPEC [4,5] for GCC Tang B/C stage II/III/IV**

**Follow-up: as per colon cancer of same stage**

Tang A: 5yrDFS - 85%

Tang B: 3yrDFS - 15%

**Relapsed metastatic disease**

Palliative chemotherapy - usually FOLFOX or Capox

**Inoperable disease or residual disease post-surgery**

**For more information, please visit our website:**

[www.ukinets.org](http://www.ukinets.org)
Goblet cell carcinoma (GCC) of the appendix are very rare epithelial neoplasms with malignant behaviour: incidence 0.01-0.05/100 000 population/year.

Goblet cell carcinoma of the appendix should be considered as a completely different entity, pathologically and prognostically, to pure neuroendocrine tumours of the appendix. Two thirds of cases are incidental findings after appendicectomy or ileo-caecal resection for abdominal pain and right iliac fossa mass.

Metastasis found at presentation (most commonly to peritoneum, omentum, ovaries, liver) in approximately 10% of tumours.

Consideration should be given to refer all patients diagnosed with GCC to a specialist centre (NET/Colorectal) for MDT review of diagnosis and treatment plan development.

Diagnostic workup:
CT scan of the thorax, abdomen and pelvis to look for metastasis. Alternatively, MRI of abdomen and pelvis can be performed.

Somatostatin receptor imaging (SRI) is very rarely positive and should not be done routinely. FDG PET may be useful in detecting disseminated disease in high grade tumours.

Tumour markers, CEA, CA 19-9 and CA 125 are more likely to be positive than neuroendocrine markers. Routine measurement of chromogranin A is not recommended.

Pathological review: use of Tang criteria may help in prognostication regarding relapse and survival. This is part of RCPath appendiceal neuroendocrine tumour dataset. Review by specialist GI or neuroendocrine histopathologist is recommended.

Staging according to UICC/AJCC as for adenocarcinoma of the appendix.

Treatment:
Localised disease: After appendicectomy recommendations are that a completion right hemicolectomy (within 3 months of initial surgery) should be considered. However, good evidence is lacking as to the benefits of this in terms of relapse free and overall survival, particularly in small (T1/2 N0) and low grade (Tang A) tumours. Such an approach needs to be individualised and discussed with patients.

In view of risk of peritoneal spread to ovaries it has been suggested that prophylactic bilateral salpingo-oophorectomy may be beneficial to improve relapse free survival. Good evidence is lacking for this and it needs to be discussed with patients on a case by case basis.

Cytoreductive surgery +/- hyperthermic intra-peritoneal chemotherapy (HIPEC) should also be considered on an individual patient basis. Referral to national peritoneal cancer services (Manchester / Basingstoke ) for MDT review or advice. Patients who may benefit the most are incompletely resected GCC with stage II/III/IV [4].

Chemotherapy:
Adjuvant chemotherapy – not evidence based but can be considered in cases with high risk of relapse, e.g. GCC Tang B/C and/or stage II/III/IV also following cytoreductive surgery +/- HIPEC is stage III/IV [4,5].

Palliative chemotherapy: A 5-fluorouracil based chemotherapy combination is recommended. FOLFIRI (+/- cetuximab) as per colorectal regimens.

Follow up:
Median overall survival varies depending on stage and grade (trend to significance of Tang classification on multivariate analysis in a number of series) – e.g. 25 months in patients presenting with peritoneal disease, 43 – 83 months in retrospective single centre case series of patients with popliteal metastasis.

In patients fit enough for further intervention appropriate clinical, biochemical and imaging follow up ( depending on stage and grade ) should be performed. This may be most appropriate via colorectal MDT as per equivalent colorectal adenocarcinoma protocol. However, follow up should be considered for a longer period as significant risk of relapse remains after 5 years.